Brokerages Set uniQure (NASDAQ:QURE) PT at $17.00

uniQure (NASDAQ:QURE) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $17.00.

Several brokerages have recently commented on QURE. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 target price on shares of uniQure in a report on Wednesday, November 6th. Raymond James reissued an “outperform” rating and issued a $20.00 price objective on shares of uniQure in a research note on Thursday, October 10th. Royal Bank of Canada decreased their price objective on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Wednesday, November 6th. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a research note on Thursday, October 17th.

uniQure Stock Down 1.1 %

Shares of QURE opened at $5.78 on Wednesday. uniQure has a 12 month low of $3.73 and a 12 month high of $11.35. The firm’s 50 day moving average is $5.93 and its 200-day moving average is $5.94. The stock has a market capitalization of $281.73 million, a PE ratio of -1.18 and a beta of 0.90. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. Equities research analysts forecast that uniQure will post -3.81 EPS for the current year.

Institutional Trading of uniQure

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after buying an additional 109,740 shares in the last quarter. Acadian Asset Management LLC raised its stake in uniQure by 133.1% during the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock worth $3,189,000 after buying an additional 350,291 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in uniQure by 49.1% during the third quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock worth $1,338,000 after buying an additional 89,400 shares during the last quarter. Privium Fund Management B.V. increased its position in shares of uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after acquiring an additional 104,500 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of uniQure during the second quarter worth about $79,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.